Guidelines for the Quality Control of Population Pharmacokinetic-Pharmacodynamic Analyses: an Industry Perspective

被引:28
作者
Bonate, P. L. [1 ]
Strougo, A. [2 ]
Desai, A. [1 ]
Roy, M. [1 ]
Yassen, A. [2 ]
van der Walt, J. S. [2 ]
Kaibara, A. [3 ]
Tannenbaum, S. [1 ]
机构
[1] Astellas Pharma Global Dev, Northbrook, IL 60062 USA
[2] Astellas Pharma Global Dev, NL-2353W Leiderdorp, Netherlands
[3] Astellas Pharma Inc, Itabashi Ku, Tokyo 1748612, Japan
关键词
modeling; NONMEM; quality assurance; VALIDATION; MODEL;
D O I
10.1208/s12248-012-9387-9
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Quality population modeling and simulation analyses and reports are something every modeler desires. However, little attention in the literature has been paid to what constitutes quality regarding population analyses. Very rarely do published manuscripts contain any statement about quality assurance of the modeling results contained therein. The purpose of this manuscript is to present guidelines for the quality assurance of population analyses, particularly with regards to the use of NONMEM from an industrial perspective. Quality guidelines are developed for the NONMEM installation itself, NONMEM data sets, control streams, output listings, output data files and resultant post-processing, reporting of results, and the review processes. These guidelines were developed to be thorough yet practical, though are not meant to be completely comprehensive. It is our desire to ensure that what is reported accurately reflects the collected data, the modeling process, and model outputs for a modeling project.
引用
收藏
页码:749 / 758
页数:10
相关论文
共 16 条
[1]  
[Anonymous], 1998, INT C HARM TECHN REQ
[2]  
[Anonymous], VALIDATION POPULATIO
[3]   Improving document review practices in pharmaceutical companies [J].
Bernhardt, SA .
JOURNAL OF BUSINESS AND TECHNICAL COMMUNICATION, 2003, 17 (04) :439-473
[4]  
Bonate PL, 2002, ANN M AM ASS PHARM S
[5]   A population pharmacokinetic model for docetaxel (Taxotere(R)): Model building and validation [J].
Bruno, R ;
Vivier, N ;
Vergniol, JC ;
DePhillips, SL ;
Montay, G ;
Sheiner, LB .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1996, 24 (02) :153-172
[6]   Validation of a population pharmacokinetic model for adjunctive lamotrigine therapy in children [J].
Chen, C .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 50 (02) :135-145
[7]   VALIDATION OF SIMPLE AND COMPLEX-MODELS IN PHYSIOLOGY AND MEDICINE [J].
COBELLI, C ;
CARSON, ER ;
FINKELSTEIN, L ;
LEANING, MS .
AMERICAN JOURNAL OF PHYSIOLOGY, 1984, 246 (02) :R259-R266
[8]  
Edholm M, 2011, EUR MED AG EUR FED P
[9]  
EMEA, 2007, Guideline on reporting the results of population pharmacokinetic analyses
[10]   Population pharmacokinetics of clinafloxacin in healthy volunteers and patients with infections - Experience with heterogeneous pharmacokinetic data [J].
Frame, B ;
Koup, J ;
Miller, R ;
Lalonde, R .
CLINICAL PHARMACOKINETICS, 2001, 40 (04) :307-315